Latest News
Kymera Therapeutics reports start of Phase 2 atopic dermatitis trial for KT-474, triggering USD15m payment from Sanofi
7 December 2023 - Clinical-stage biopharmaceutical company Kymera Therapeutics Inc (NASDAQ:KYMR) announced on Thursday that the first patient has been dosed in the randomized Phase 2 clinical trial (ADVANTA) for KT-474 (SAR444656) in atopic dermatiti...
Ipsen and GENFIT granted priority review for elafibranor NDA in PBC treatment
7 December 2023 - Biopharmaceutical companies Ipsen (Euronext Paris:IPN) (ADR:IPSEY) and GENFIT (Nasdaq:GNFT) (Euronext Paris:GNFT) reported on Thursday that the US Food and Drug Administration (FDA) has granted priority review to the New Drug Applic...
Sanofi announces positive Phase 3 results for Sarclisa in multiple myeloma trial
7 December 2023 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) on Thursday reported a successful outcome from the Phase 3 IMROZ trial evaluating Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalid...
Innovent Biologics expands licensing contract with Synaffix
7 December 2023 - Innovent Biologics, Inc. (HKEX: 01801), a China-based biopharmaceutical company, announced on Wednesday that it has expanded its licensing contract with Netherlamds-based Synaffix BV, a Lonza company (SIX:LONN) focused on commercial...
Petauri Health names new board members
7 December 2023 - Petauri Health, a New York-based, purpose-built pharmaceutical services platform, announced on Wednesday that it has named William Fleming and James Robinson as members of the company's board of directors.Fleming has around 30-...